Condition: Chronic Obstructive Pulmonary Disease · Sponsor: University Hospital, Montpellier
The main objective of this trial is to compare the exacerbation number over 12 months of follow-up between a group of patients with COPD treated according to standardized management (azithromycin prescribed in the event of severe sputum according to the CASA-Q score , standardized comparator arm) and a similar group in which azithromycin is prescribed based on mucus rheology (experimental arm) or CASA-Q.
This description comes directly from the study's public registry record.
Jérémy Charriot, MD · 04 67 33 67 33 · j-charriot@chu-montpellier.fr
Arnaud BOURDIN, MD · 04 67 33 67 33 · a-bourdin@chu-montpellier.fr
Always discuss trial participation with your own doctor first.
| University Hospitals of Bordeaux | Bordeaux, France | Recruiting |
| University Hospitals of Montpellier | Montpellier, France | Recruiting |
| University Hospitals of Toulouse | Toulouse, France | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04339270